America's Blood Centers and ADRP Release Updated U.S. Blood Donation Statistics and Public Messaging Guide
22. Januar 2024 13:34 ET
|
America’s Blood Centers
Washington, DC, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Washington, DC – America’s Blood Centers (ABC), the national organization of community-based, independent blood centers that supply 60 percent of...
ADRP Announces Rebranding, Becomes the Association for Blood Donor Professionals
10. Mai 2023 17:17 ET
|
America’s Blood Centers
Washington, DC, May 10, 2023 (GLOBE NEWSWIRE) -- ADRP, the international division of America’s Blood Centers, today announced an extensive rebranding effort reflecting the organization’s growth and...
ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa
11. Dezember 2019 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
21. November 2019 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
09. September 2019 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)
12. August 2019 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals
29. Oktober 2018 07:33 ET
|
ProQR Therapeutics N.V.
ProQR receives exclusive worldwide license for IONIS-RHO-2.5Rx, now QR-1123, for autosomal dominant retinitis pigmentosa (adRP), a rare inherited form of blindness with no approved therapy A first in...